Edition:
India

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

3.12USD
2:29am IST
Change (% chg)

$0.08 (+2.46%)
Prev Close
$3.05
Open
$3.10
Day's High
$3.15
Day's Low
$3.08
Volume
11,074
Avg. Vol
27,587
52-wk High
$6.85
52-wk Low
$2.95

Select another date:

Mon, Nov 20 2017

BRIEF-Proqr reports loss of EUR 0.42 per share​

* Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​ Source text for Eikon: Further company coverage:

BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110

* ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness

BRIEF-JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14

* JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​ Source text: (http://bit.ly/2yhtqSA) Further company coverage:

BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010

* ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis

BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313

* ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences

BRIEF-ProQR Therapeutics spins out Amylon Therapeutics

* ProQR therapeutics - spun out Amylon Therapeutics, a privately-held company focused on development of therapies for central nervous system disorders

BRIEF-ProQR Q2 loss per share EUR 0.47

* ProQR Therapeutics - enrollment completed in phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September Source text for Eikon: Further company coverage:

BRIEF-Invus Public Equities reports 6 pct passive stake in Proqr Therapeutics

* Invus Public Equities reports a 6 percent passive stake in Proqr Therapeutics NV as of july 3, 2017 - sec filing Source text - http://bit.ly/2sJLPGD Further company coverage:

BRIEF-Proqr to present QR-010 data at European Cystic Fibrosis Society conference

* Proqr to present QR-010 data at the European Cystic Fibrosis Society conference and provides an update on the ongoing phase 1b trial

Select another date: